-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In the randomized, placebo-controlled, phase 3 TAGS study, Trifluridine and tipiracil (trifluridine tipiracil , FTD /TPI) compared with placebo in previously treated metastatic gastric/gastroesophageal junction cancer ( A survival benefit and a manageable safety profile were shown in patients with mGC/GEJC)
In the randomized, placebo-controlled, phase 3 TAGS study, Trifluridine and tipiracil (trifluridine tipiracil , FTD /TPI) compared with placebo in previously treated metastatic gastric/gastroesophageal junction cancer ( A survival benefit and a manageable safety profile were shown in patients with mGC/GEJC)
In the TAGS study, mGC/GEJC patients with ≥2 lines of prior therapy were randomized (2:1) to receive FTD/TPI 35 mg/m2 or placebo, plus best supportive care
In the TAGS study, mGC/GEJC patients with ≥2 lines of prior therapy were randomized (2:1) to receive FTD/TPI 35 mg/m2 or placebo, plus best supportive care
Of the 507 randomized patients (337 FTD/TPI, 170 placebo), 279 (55%) were aged <65 years, 228 patients (45%) ≥65 years, and ≥75 years 69 patients (14%)
In all 3 age groups, patients who received FTD/TPI lasted longer than those who received placebo
Among patients <65 years old, median OS was 5.
Differences between different age treatment groups and OSPFS Differences between different age treatment groups and OSPFS
Likewise, FTD/TPI treatment improved patient PFS compared with placebo in all 3 age groups
Likewise, FTD/TPI treatment improved patient PFS compared with placebo in all 3 age groups
Among patients <65 years old, the median time to physical deterioration to ECOG ≥2 was 4.
Differences in the time to physical malignancy between treatment groups of different ages
In conclusion, the subgroup analysis of the TAGS study showed that FTD/TPI therapy in mGC/GEJC patients who had received 2 or more previous treatments was still effective and tolerable regardless of age
In conclusion, the subgroup analysis of the TAGS study showed that FTD/TPI therapy in mGC/GEJC patients who had received 2 or more previous treatments was still effective and tolerable regardless of age
Original source:
Mansoor W, Arkenau HT, Alsina M, Shitara K, Thuss-Patience P, Cuffe S, Dvorkin M, Park D, Ando T, Van Den Eynde M, Beretta GD, Zaniboni A, Doi T, Tabernero J, Ilson DH, Makris L, Benhadji KA, Van Cutsem E.
Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study.
Gastric Cancer.
2021 Jul;24(4):970-977.
doi: 10.
1007/s10120 -021-01156-x.
Epub 2021 Mar 13.
PMID: 33713215; PMCID: PMC8205879.
Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study.
Gastric Cancer.
2021 Jul;24(4):970-977.
doi: 10.
1007/s10120 -021-01156-x.
Epub 2021 Mar 13.
PMID: 33713215; PMCID: PMC8205879.
Leave a comment here
